MYGN Myriad Genetics Inc
Price (delayed)
$10.21
Market cap
$932.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.41
Enterprise value
$970.17M
Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing
Highlights
The gross profit is up by 13% year-on-year and by 2.8% since the previous quarter
Myriad Genetics's revenue has increased by 11% YoY
The EPS has soared by 56% YoY but it has contracted by 10% from the previous quarter
The company's net income has surged by 52% YoY but it fell by 10% QoQ
The quick ratio has declined by 17% year-on-year and by 7% since the previous quarter
The company's equity fell by 10% YoY and by 4.2% QoQ
Key stats
What are the main financial stats of MYGN
Market
Valuations
Earnings
Shares outstanding
91.31M
Market cap
$932.27M
Enterprise value
$970.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.33
Price to sales (P/S)
1.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.16
Revenue
$837.6M
Gross profit
$585.4M
Operating income
-$123.5M
Net income
-$127.3M
EBIT
-$120.7M
EBITDA
-$50M
Free cash flow
-$38.4M
Per share
Balance sheet
Liquidity
EPS
-$1.41
EPS diluted
-$1.41
Free cash flow per share
-$0.42
Book value per share
$7.7
Revenue per share
$9.25
TBVPS
$5.29
Total assets
$1.03B
Total liabilities
$326.5M
Debt
$140.3M
Equity
$701.1M
Working capital
$133.9M
Debt to equity
0.2
Current ratio
1.82
Quick ratio
1.36
Net debt/EBITDA
-0.76
Margins
Efficiency
Dividend
EBITDA margin
-6%
Gross margin
69.9%
Net margin
-15.2%
Operating margin
-14.7%
Return on assets
-11.8%
Return on equity
-17.4%
Return on invested capital
-32.4%
Return on capital employed
-14%
Return on sales
-14.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MYGN stock price
How has the Myriad Genetics stock price performed over time
Intraday
-1.92%
1 week
-2.95%
1 month
-30.31%
1 year
-52.58%
YTD
-25.53%
QTD
-25.53%
Financial performance
How have Myriad Genetics's revenue and profit performed over time
Revenue
$837.6M
Gross profit
$585.4M
Operating income
-$123.5M
Net income
-$127.3M
Gross margin
69.9%
Net margin
-15.2%
The net margin has soared by 57% YoY but it has contracted by 8% from the previous quarter
The company's operating margin has surged by 57% YoY but it fell by 4.3% QoQ
The operating income has soared by 52% YoY but it fell by 7% QoQ
The company's net income has surged by 52% YoY but it fell by 10% QoQ
Growth
What is Myriad Genetics's growth rate over time
Valuation
What is Myriad Genetics stock price valuation
P/E
N/A
P/B
1.33
P/S
1.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.16
The EPS has soared by 56% YoY but it has contracted by 10% from the previous quarter
MYGN's price to book (P/B) is 50% lower than its last 4 quarters average of 2.7 and 36% lower than its 5-year quarterly average of 2.1
The company's equity fell by 10% YoY and by 4.2% QoQ
The P/S is 55% lower than the 5-year quarterly average of 2.5 and 53% lower than the last 4 quarters average of 2.4
Myriad Genetics's revenue has increased by 11% YoY
Efficiency
How efficient is Myriad Genetics business performance
The ROS has soared by 58% YoY but it has contracted by 4.3% from the previous quarter
MYGN's return on equity is up by 50% year-on-year but it is down by 13% since the previous quarter
Myriad Genetics's return on assets has increased by 48% YoY but it has decreased by 12% QoQ
The return on invested capital has grown by 47% year-on-year but it has declined by 8% since the previous quarter
Dividends
What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MYGN.
Financial health
How did Myriad Genetics financials performed over time
The quick ratio has declined by 17% year-on-year and by 7% since the previous quarter
The company's total liabilities fell by 10% YoY and by 7% QoQ
The debt is 80% less than the equity
The company's equity fell by 10% YoY and by 4.2% QoQ
The debt has contracted by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.